A Phase 3, Long-Term, Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects

Trial Profile

A Phase 3, Long-Term, Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Botulinum toxin B (Primary)
  • Indications Sialorrhoea
  • Focus Adverse reactions; Registrational
  • Acronyms OPTIMYST
  • Sponsors US WorldMeds
  • Most Recent Events

    • 25 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 10 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 04 Oct 2016 Planned End Date changed from 1 Jan 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top